Cipla

1st September 2015

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
11, av de la Porte-Neuve,
L-2227 Luxemberg

Dear Sirs,

We are forwarding herewith copy of press release titled "Cipla appoints Umang Vohra and Prabir Jha to its management team".

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary

Encl.: as above

Cipla appoints Umang Vohra and Prabir Jha to its management team

India, Mumbai 1 September 2015: Today, Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is delighted to announce the appointment of **Umang Vohra as Global Chief Financial and Strategy Officer** and **Prabir Jha as Global Chief People Officer** effective 1st October 2015.

Until recently Umang was the Head of the North America business for Dr Reddy's. He was instrumental in growing this business by over 60% to cross a 1bn USD sales, almost half the revenues of Dr Reddy's, through several business development partnerships, acquisitions as well as growing the oncology health system business. Prior to this, Umang was the global CFO of Dr. Reddy's for four years and was widely credited with the significant improvement in the company's ROCE (return on capital employed). Prior to Dr Reddy's, he worked with PepsiCo and Eicher Motors. In addition to the Finance role, Umang will be responsible for Strategy, Portfolio, Business Development, Mergers and Acquisitions and Business Technology.

Commenting on his appointment, Subhanu Saxena, MD and Global CEO, Cipla Ltd said "We are delighted that Umang Vohra is joining the leadership team at Cipla. He brings deep insights about the global generics industry as well as an understanding of value creation through his background in leading business and finance roles."

Prabir Jha will join Cipla as the Global Chief People Officer. In addition to providing leadership to the Human Resources function globally for the company, he will lead the Corporate Communications and Administration functions as well. Prabir is an alumnus of St. Stephen's College and XLRI Jamshedpur. After a decade long tenure as a civil servant, he has pursued a corporate career in Human Resources. As the Chief HR Officer at some of the country's leading corporations like Dr Reddy's, Tata Motors and most recently, Reliance Industries, Prabir has built a solid reputation as an organisation transformation strategist and a very progressive HR practitioner.

Commenting on his appointment, Samina Vaziralli, Executive Director who has been interim Head of HR said, "We are in a very exciting stage of growth for Cipla. We truly believe focusing and building on human capital is one of the ultimate sources of sustainable, competitive advantage. Having Prabir on our executive leadership team, to help us steer this agenda will ensure that our commitment to cutting edge people practices is at the heart of everything we do at Cipla."

Ends

About Cipla Limited

Cipla Limited is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems.

Media Contacts:
Corporate Communications

Charlotte Chunawala
Mobile: +91 7506257377
E Mail: charlotte.chunawala@cipla.com;

Pallavi Golar
Mobile: +91 9833641788
E Mail: pallavi.golar@cipla.com